chromatography-2016_scientifictracks-abstracts

22 / 32

Notes:
Page 45
Chromatography 2016
September 21-23, 2016
Volume 7, Issue 5(Suppl) J Chromatogr Sep Tech 2016
ISSN: 2157-7064 JCGST, an open access journal
conferenceseries .com
September 21-23, 2016 Amsterdam, Netherlands
World Congress on Chromatography
Automated harvesting and 2-step purification of eight 1-L unclarified mammalian cell-culture broths
containing antibodies using a novel configuration on ÄKTATM pure
Fabian Holenstein1, Christer Eriksson 2, Ioana Erlandsson2, Jill Simon2, Lars Erni2, Katharina Stein3, Michael Glaettli3, Andres Tschupp1, Adriana Milicov1,
Patrick Schindler1, Thomas Pietzonka1, Johanna Koelln1 and Jean-Marc Schlaeppi1
1Novartis Institutes for Biomedical Research, Switzerland
2GE Healthcare Life Sciences, Sweden
3GE-Europe Glattbrugg, Switzerland
Therapeutic antibodies represent one of the fastest growing segments in the pharmaceutical market. The growth of the
segment has necessitated development of new efficient and cost saving platforms for the preparation and analysis of early
candidates for faster and better antibody selection and characterization. We report a new integrated platform for unattended
harvesting and 2-step purification of antibodies expressed transiently in HEK293T-cells at the 1-liter scale. The system consists
of two bench-top preparative chromatography instruments connected to a central unit with eight disposable filtrations devices
used for loading and filtering the crude biomass feeds. Our end-product QC analysis demonstrates that the quality of the
material prepared by the 2-step automated purification is fully comparable to the material purified by standard manual 2-step
purification. Average recoveries were also comparable to those obtained by manual purification, indicating that this automated
system allows the cost-efficient preparation of therapeutic antibodies in the 20-200 mg range, and covers the requirements for
early in vitro and in vivo profiling of drug candidates.
Biography
Fabian Holenstein holds an Engineering degree in Biotechnology and a Master’s in Pharmaceutical Biotechnology. He works as a Senior Scientist in the section of
protein production and antibodies at Novartis Institute for Biomedical Research in Basel/Switzerland.
Fabian Holenstein et al., J Chromatogr Sep Tech 2016, 7:5(Suppl)